Literature DB >> 1527537

EDMUS, a European database for multiple sclerosis.

C Confavreux1, D A Compston, O R Hommes, W I McDonald, A J Thompson.   

Abstract

EDMUS is a minimal descriptive record developed for research purposes to document clinical and laboratory data in patients with multiple sclerosis (MS). It has been designed by a committee of the European Concerted Action for MS, organised under the auspices of the Commission of the European Communities. The software is user-friendly and fast, with a minimal set of obligatory data. Priority has been given to analytical data and the system is capable of automatically generating data, such as diagnosis classification, using appropriate algorithms. This procedure saves time, ensures a uniform approach to individual cases and allows automatic updating of the classification whenever additional information becomes available. It is also compatible with future developments and requirements since new algorithms can be entered in the programme when necessary. This system is flexible and may be adapted to the users needs. It is run on Apple and IBM-PC personal microcomputers. Great care has been taken to preserve confidentiality of the data. It is anticipated that this "common" language will enable the collection of appropriate cases for specific purposes, including population-based studies of MS and will be particularly useful in projects where the collaboration of several centres is needed to recruit a critical number of patients.

Entities:  

Mesh:

Year:  1992        PMID: 1527537      PMCID: PMC489202          DOI: 10.1136/jnnp.55.8.671

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  9 in total

1.  FURTHER NOTES ON DISABILITY EVALUATION IN MULTIPLE SCLEROSIS, WITH SCALE MODIFICATIONS.

Authors:  J F KURTZKE
Journal:  Neurology       Date:  1965-07       Impact factor: 9.910

2.  PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS.

Authors:  G A SCHUMACHER; G BEEBE; R F KIBLER; L T KURLAND; J F KURTZKE; F MCDOWELL; B NAGLER; W A SIBLEY; W W TOURTELLOTTE; T L WILLMON
Journal:  Ann N Y Acad Sci       Date:  1965-03-31       Impact factor: 5.691

3.  On the evaluation of disability in multiple sclerosis.

Authors:  J F KURTZKE
Journal:  Neurology       Date:  1961-08       Impact factor: 9.910

4.  Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.

Authors:  S L Hauser; D M Dawson; J R Lehrich; M F Beal; S V Kevy; R D Propper; J A Mills; H L Weiner
Journal:  N Engl J Med       Date:  1983-01-27       Impact factor: 91.245

5.  New diagnostic criteria for multiple sclerosis: guidelines for research protocols.

Authors:  C M Poser; D W Paty; L Scheinberg; W I McDonald; F A Davis; G C Ebers; K P Johnson; W A Sibley; D H Silberberg; W W Tourtellotte
Journal:  Ann Neurol       Date:  1983-03       Impact factor: 10.422

6.  [Immunochemical estimation of IgG and albumin in cerebrospinal fluid].

Authors:  B Delpech; E Lichtblau
Journal:  Clin Chim Acta       Date:  1972-03       Impact factor: 3.786

7.  Magnetic resonance imaging of the head in the diagnosis of multiple sclerosis: a prospective 2-year follow-up with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT.

Authors:  K H Lee; S A Hashimoto; J P Hooge; L F Kastrukoff; J J Oger; D K Li; D W Paty
Journal:  Neurology       Date:  1991-05       Impact factor: 9.910

8.  Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).

Authors:  J F Kurtzke
Journal:  Neurology       Date:  1983-11       Impact factor: 9.910

9.  Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients.

Authors:  C Confavreux; G Aimard; M Devic
Journal:  Brain       Date:  1980-06       Impact factor: 13.501

  9 in total
  45 in total

1.  MOG antibody-related disorders: common features and uncommon presentations.

Authors:  Álvaro Cobo-Calvo; Anne Ruiz; Hyacintha D'Indy; Anne-Lise Poulat; Maryline Carneiro; Nicolas Philippe; Françoise Durand-Dubief; Kumaran Deiva; Sandra Vukusic; Vincent Desportes; Romain Marignier
Journal:  J Neurol       Date:  2017-08-02       Impact factor: 4.849

2.  Childhood multiple sclerosis and related disorders.

Authors:  Amna Al-Futaisi
Journal:  Oman Med J       Date:  2007-10

Review 3.  Treatment decisions in multiple sclerosis - insights from real-world observational studies.

Authors:  Maria Trojano; Mar Tintore; Xavier Montalban; Jan Hillert; Tomas Kalincik; Pietro Iaffaldano; Tim Spelman; Maria Pia Sormani; Helmut Butzkueven
Journal:  Nat Rev Neurol       Date:  2017-01-13       Impact factor: 42.937

4.  European validation of a standardized clinical description of multiple sclerosis.

Authors:  Maria Pia Amato; Jerome Grimaud; Iuliana Achiti; Maria Letizia Bartolozzi; Patrice Adeleine; Hans-Peter Hartung; Ludwig Kappos; Alan Thompson; Maria Trojano; Sandra Vukusic; Christian Confavreux
Journal:  J Neurol       Date:  2004-12       Impact factor: 4.849

Review 5.  Secondary Progressive Multiple Sclerosis: Definition and Measurement.

Authors:  Domenico Plantone; Floriana De Angelis; Anisha Doshi; Jeremy Chataway
Journal:  CNS Drugs       Date:  2016-06       Impact factor: 5.749

6.  Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria.

Authors:  G Edan; D Miller; M Clanet; C Confavreux; O Lyon-Caen; C Lubetzki; B Brochet; I Berry; Y Rolland; J C Froment; E Cabanis; M T Iba-Zizen; J M Gandon; H M Lai; I Moseley; O Sabouraud
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-02       Impact factor: 10.154

7.  Ozone, NO2 and PM10 are associated with the occurrence of multiple sclerosis relapses. Evidence from seasonal multi-pollutant analyses.

Authors:  Maxime Jeanjean; Marie-Abele Bind; Jonathan Roux; Jean-Claude Ongagna; Jérôme de Sèze; Denis Bard; Emmanuelle Leray
Journal:  Environ Res       Date:  2018-02-06       Impact factor: 6.498

8.  Multiple sclerosis with a progressive course from onset in Lorraine-Eastern France.

Authors:  M Debouverie; S Louis; S Pittion-Vouyovitch; T Roederer; H Vespignani
Journal:  J Neurol       Date:  2007-06-25       Impact factor: 4.849

9.  3,4-diaminopyridine safety in clinical practice: an observational, retrospective cohort study.

Authors:  Laurent Flet; Elisabeth Polard; Olivia Guillard; Emmanuelle Leray; Hervé Allain; Loïc Javaudin; Gilles Edan
Journal:  J Neurol       Date:  2010-01-08       Impact factor: 4.849

10.  Evidence for a two-stage disability progression in multiple sclerosis.

Authors:  Emmanuelle Leray; Jacqueline Yaouanq; Emmanuelle Le Page; Marc Coustans; David Laplaud; Joël Oger; Gilles Edan
Journal:  Brain       Date:  2010-04-27       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.